Quick Answer
Entrada Therapeutics, Inc. reported Cash and Equivalents of $90.39 million for fiscal year 2025.
Entrada Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $90.39M | -10.7% |
| 2024 | $101.21M | +49.7% |
| 2023 | $67.60M | +49.7% |
| 2022 | $45.16M | -84.5% |
| 2021 | $291.06M | +645.5% |
| 2020 | $39.05M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $93.29M | +19.5% | +28.7% |
| June 30, 2025 | $72.48M | -60.9% | +6.8% |
| March 31, 2025 | $67.84M | -0.9% | -33.0% |
| December 31, 2024 | $101.21M | +49.7% | +29.7% |
| September 30, 2024 | $78.05M | +50.4% | -57.9% |
| June 30, 2024 | $185.25M | +132.3% | +170.7% |
| March 31, 2024 | $68.44M | -69.9% | +1.2% |
| December 31, 2023 | $67.60M | +49.7% | +30.3% |
- Entrada Therapeutics, Inc. showed a decrease of -10.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s cash and equivalents has grown by 131.5% (from $39.05 million to $90.39 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: